Sorry, you need to enable JavaScript to visit this website.

A Safety and Efficacy Study of Abrocitinib Tablets in Participants Aged 12 Years and Older With Atopic Dermatitis in India

A Randomized, Open-Label, Parallel-Group Study to Evaluate the Safety and Efficacy of Abrocitinib 100 mg and 200 mg Tablets in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis in India

Category & Conditions: Skin Diseases and Conditions
Medicine: abrocitinib (PF-04965842)
ClinicalTrials.gov Identifier (NCT): NCT05375929
Protocol ID: B7451094
PrintDownload
Open Plain Language Summary Result: Click here